PDCD1 and metastatic malignant neoplasm: Indeed, blocking antibodies that target inhibitory checkpoint molecules (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] and programmed cell death protein 1 [PD1]) have shown to be highly efficient in experimental studies and relatively effective in clinical trials involving patients with metastatic cancer[7].